Cheryl Corcoran, MD

Expertise in: 
Psychotic Disorders, ECT, Depression
Board Certifications: 
Psychiatry
Accepting New Patients
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

Psychotic Disorders, ECT, Depression

Academic Appointments

  • Assistant Professor of Psychiatry at CUMC

Dr. Corcoran has expertise in schizophrenia, specifically its early stages. Her research focus has been to identify biomarkers of risk and illness progression in schizophrenia: in collaboration, she has identified increased limbic activation, cognitive disorganization, social cognitive deficits, and sensory processing abnormalities as risk biomarkers for schizophrenia. She is now utilizing the tools of cognitive neuroscience, including neural imaging, EEG and brain stimulation, to more fully characterize these deficits, such that early intervention strategies can be developed and implemented. This includes a focus on negative symptoms such as low motivation, which accounts for the main functional impairment of schizophrenia, apart from psychotic symptoms. Dr. Corcoran has also studied the role of environment in schizophrenia risk and onset, including stress and cannabis use, as well as stigma and recovery related to schizophrenia.

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Credentials & Experience

Education & Training

  • 1990 Harvard Medical School
  • Internship: 1991 Cambridge Health Alliance
  • Residency: 1994 Cambridge Health Alliance
  • Fellowship: 2002 NewYork-Presbyterian Hospital/Columbia University Medical Center

Board Certifications

  • Psychiatry

Research

Dr. Corcoran is interested in characterizing early stages of schizophrenia, including biomarkers, such that early intervention strategies can be developed and implemented.

In collaboration, Dr. Corcoran has identified increased limbic activation, cognitive disorganization, social cognitive deficits, and sensory processing abnormalities as risk biomarkers for schizophrenia. She is now utilizing the tools of cognitive neuroscience, including neural imaging, EEG and brain stimulation, to more fully characterize these deficits, such that early intervention strategies can be developed and implemented.

Research Interests

  • schizophrenia in its early stages
  • cognitive neuroscience
  • brain stimulation

Grants

TEMPORAL DYNAMICS OF NEUROPHYSIOLOGICAL PATTERNS AS TREATMENT TARGETS IN SZ (Federal Gov)

Feb 1 2016 - Jan 31 2021

STIGMA ASSOCIATED WITH A HIGH-RISK STATE FOR PSYCHOSIS AMONG ADOLESCENTS AND YOUNG ADULTS: IMPACTS ON IDENTITY AND SOCIAL INTEGRATION (Federal Gov)

May 22 2012 - Mar 31 2018

THOUGHT DISORDER AND SOCIAL COGNITION IN CLINICAL RISK STATES FOR SCHIZOPHRENIA (Federal Gov)

Jul 1 2016 - Aug 31 2017

LONGITUDINAL IMAGING OF PATIENTS AT CLINICAL RISK FOR PSYCHOSIS. (Federal Gov)

Sep 22 2011 - May 31 2017

EARLY CORTICAL PROCESSING IN SCHIZOPHRENIA (Federal Gov)

Mar 1 2014 - Feb 29 2016

THE CONTE CENTER FOR SCHIZOPHRENIA RESEARCH (Federal Gov)

Jul 23 2009 - Aug 31 2015

STIGMA ASSOCIATED WITH A HIGH-RISK STATE FOR PSYCHOSIS: POTENTIAL ADOPTION OF A CONTROVERSIAL DIAGNOSIS FOR DSM-V (Private)

Jul 15 2011 - Jul 14 2013

Selected Publications

  • Kayser J, Tenke CE, Kroppmann CJ, Alschuler DM, Ben-David S, Fekri S, Bruder GE, Corcoran C: Olfaction in the Psychosis Prodrome: Electrophysiological and Behavioral Measures of Odor Detection. International Journal of Psychophysiology 2013
  • Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, Inbar BP, Corcoran CM, Lieberman JA, Moore H, Small SA.: Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013;78: 81-93
  • Corcoran CM, Kimhy D, Parrilla-Escobar MA, Cressman VL, Stanford AD, Thompson J, David SB, Crumbley A, Schobel S, Moore H, Malaspina D.: The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis. Psychological Medicine 2011;41: 251-261
  • Corcoran CM, First MB, Cornblatt B.: The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophrenia Research 2010;120: 16-22
  • Corcoran C, Whitaker A, Coleman E, Fried J, Feldman J, Goudsmit N, Malaspina D.: Olfactory deficits, cognition and negative symptoms in early onset psychosis. Schizophrenia Research 2005;80: 283-293